SCHEMBL890516

SCHEMBL890516

CC(c1nc2ccc(F)cn2c(=O)c1-c1ccccn1)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 10/20 0.54
PIK3R1 P27986 2/20 0.42
PIK3CB P42338 2/20 0.42
PIK3CG P48736 2/20 0.42
PIK3CA P42336 1/20 0.42
TP53 P04637 2/20 0.37
GAA P10253 2/20 0.37
MAPT P10636 1/20 0.37
BRD4 O60885 1/20 0.37
MET P08581 1/20 0.36
FADS1 O60427 1/20 0.36
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
JAK2 O60674 2/20 0.35
JAK3 P52333 2/20 0.35
JAK1 P23458 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL890587 0.84 PIK3CD (0.58) PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA
SCHEMBL890605 0.81 PIK3CD (0.37) PIK3CDPIK3R1PIK3CBPIK3CGTP53
SCHEMBL890593 0.78 PIK3CD (0.52) PIK3CDTP53GAAMAPTKMT2A
SCHEMBL2729736 0.73 PIK3CD (0.51) PIK3CDPIK3CBPIK3CGPIK3CA
SCHEMBL890621 0.72 KDM4E (0.41) PIK3CDPIK3CBPIK3CGPIK3CATP53
SCHEMBL890586 0.71 PIK3CD (0.78) PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA
SCHEMBL890526 0.71 PIK3CD (0.78) PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA
SCHEMBL890373 0.71 PIK3CD (0.78) PIK3CDPIK3R1PIK3CBPIK3CGPIK3CA
SCHEMBL23212709 0.70 LMNA (0.42) BRD4METNPC1LMNAKMT2A
SCHEMBL890545 0.68 KDM4E (0.44) PIK3CDGAAMAPTRAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754089-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-06-17 US disclosed
US-8754089-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-06-17 US disclosed
US-8754089-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-06-17 US disclosed
EP-2445898-A2 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES AS PI3K INHIBITORS Amgen, Inc (US) 2012-05-02 EP disclosed
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-05 US disclosed
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-05 US disclosed
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-05 US disclosed
WO-2010151735-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed
WO-2010151735-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 PIK3CD 24/4885PIK3R1 48/4885PIK3CB 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.